A company developing treatments for dermatology and immunology.
Aclaris has two commercialized products in its portfolio, Eskata and Rhofade. Eskata is topical treatment for SKs (seborrheic keratoses). SKs are harmless spots that pop up as a person ages. Rhofade on the other hand, is a topical treatment for persistent facial erythema associated with rosacea in adults. Rhofade was originally developed by AllerganAllergan, which Aclaris then acquired the worldwide rights to.
No more activity to show.